Impact Biomedical (IBO) Total Liabilities (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Total Liabilities data on file, last reported at $2.4 million in Q1 2026.

• Quarterly Total Liabilities fell 82.06% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 82.06% YoY) and the FY2025 annual result came in at $1.8 million, down 85.83% from the prior year.
• Total Liabilities grew to $2.4 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $44.4 million in Q1 2024 to a low of $1.8 million in Q4 2025.
• A 5-year average of $18.9 million and a median of $15.3 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 188.53% — and 2025, when it tumbled 85.83%.
• Tracing IBO's Total Liabilities over 5 years: stood at $13.8 million in 2022, then advanced by 18.39% to $16.4 million in 2023, then slipped by 20.27% to $13.1 million in 2024, then plunged by 85.83% to $1.8 million in 2025, then climbed by 28.38% to $2.4 million in 2026.
• The last three Total Liabilities figures came in at $2.4 million (Q1 2026), $1.8 million (Q4 2025), and $27.1 million (Q3 2025), per Business Quant data.